New drug delivery systems in inflammatory bowel disease: MMX™ and tailored delivery to the gut

Current Medicinal Chemistry

Volumn 17, Issue 17, 2010, Pages 1851-1857

  Fiorino, G ^a   Fries, W ^b   de la Rue, S A ^c   Malesci, A C ^a,d   Repici, A ^a   Danese, S ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c Readable Science ^*  (United Kingdom)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Budesonide; Colitis; Crohn; Heparin; IBD; Mesalamine; MMX; Multimatrix

Indexed keywords

AMPHOPHILE; BUDESONIDE; BUDESONIDE MMX; EXCIPIENT; HEPARIN; HEPARIN MMX; MESALAMINE MMX; MESALAZINE; PARNAPARIN; PARNAPARIN MMX; POLYMER; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED DRUG RELEASE; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DYSPEPSIA; ENTERITIS; HEADACHE; HEPATITIS; HUMAN; HYDROPHILICITY; LIPOPHILICITY; MULTIMATRIX TECHNOLOGY; NAUSEA; PANCREATITIS; REMISSION; ULCERATIVE COLITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; EXCIPIENTS; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; MESALAMINE;

EID: 77953525114     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710791111170     Document Type: Article

References (30)

1. Carter, M.J.; Lobo, A.J.; Travis, S.P. Guidelines for the management of inflammatory bowel disease in adults. Gut, 2004, 53, 1-16.
2. Toruner, M.; Loftus, M. Jr.; Harmsen, W.; Zinsmeister, A.; Orenstein, R.; Sandborn, W.J.; Colombel, J.F.; Egan, L. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology, 2008, 134, 929-936.
3. ® in the human gut. Pract. Gastroenterol., 1999, 1-8.
4. Desremaux P, Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid new evidence. Aliment. Pharmacol. Ther., 2006, 24(Suppl. 1), 2-9.
5. Frieri, G.; Giacomelli, R.; Pimpo, M.; Palumbo, G.; Passacantando, A.; Pantaleoni, G.; Caprilli, R. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut, 2000, 47, 410-4.
6. Vree, T.B.; Dammers, E.; Exler, P.S.; Sörgel, F.; Bondesen, S.; Maes, R.A. Liver and gut mucosa acetylation of mesalazine in healthy volunteers. Int. J. Clin. Pharmacol. Ther., 2000, 38, 514-22.
7. Hein, D.W.; Doll, M.A.; Fretland, A.J.; Leff, M.A.; Webb, S.J.; Xiao, G.H.; Devanaboyina, U.S.; Nangju, N.A.; Feng, Y. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol. Biomarkers Prev., 2000, 9, 2942.
8. Liang, E.; Proudfoot, J.; Yazdanian, M. Mechanisms of transport and structurepermeability relationship of sulfasalazine and its analogs in Caco-2 cell monolayers. Pharm. Res., 2000, 17, 1168-74.
9. Kane, S.; Huo, D.; Aikens, J.; Hanauer, S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am. J. Med., 2003, 114, 39-43.
10. Ryrfeldt, A.; Andersson, P.; Edsbäcker, S.; Tonnesson, M.; Davies, D.; Pauwels, R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur. J. Respir. Dis. Suppl., 1982, 122, 8695.
11. Gionchetti, P.; Ardizzone, S.; Benvenuti, M.E.; Bianchi, P.G.; Biasco, G.; Cesari, P.; D'Albasio, G.; De Franchis, R.; Monteleone, G.; Pallone, F.; Ranzi, T.; Trallori, G.; Valpiani, D.; Vecchi, M.; Campieri, M. A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial. Aliment. Pharmacol. Ther., 1999, 13, 381-388.
12. Otley, A.; Steinhart, A.H. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst. Rev., 2005, 4, 1-26.
13. Edsbäcker, S.; Larsson, P.; Wollmerc, P. Gut delivery of budesonide, a locally active corticosteroid, from plain and controlled-release capsules. Eur. J. Gastroenterol. Hepatol., 2002, 14(12), 1357-1362.
14. Travis, S.P.; Stange, E.F.; Lémann, M.; Öresland, T.; Chowers, Y.; Forbes, A.; D'Haens, G.; Kitis, G.; Cortot, A.; Prantera, C.; Marteau, P.; Colombel, J.F.; Gionchetti, P.; Bouhnik, Y.; Tiret, E.; Kroesen, J.; Starlinger, M.; Mortensen, N.J. For the ECCO. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut, 2006, 55(Suppl. 1), i16-i35.
15. Prantera, C.; Viscido, A.; Biancone, L.; Francavilla, A.; Giglio, L.; Campieri, M. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflam. Bowel Dis., 2005, 11, 421-427.
16. D'Haens, G.; Hommes, D.; Engels, L.; Baert, F.; Van Der Vaaji, L.; Connor, P.; Ramage, J.; Dewitt, O.; Palmen, M.; Stephenson, D.; Joseph, R. Once daily MMX mesalazine for the treatment of mildto-moderate ulcerative colitis: a phase II, dose-ranging study. Alimentary Pharmacol. Ther., 2006, 24, 1087-1097.
17. Lichtenstein, G.R.; Kamm, M.A.; Boddu, P.; Gubergrits, N.; Lyne, A.; Butler, T.; Lees, K.; Joseph, R.E.; Sandborn, W.J. Effect of Onceor Twice-Daily MMX Mesalamine (SPD476) for the Induction of Remission of Mild to Moderately Active Ulcerative Colitis. Clin. Gastroenterol. Hepatol., 2007, 5, 95-102.
18. Kamm, M.A.; Sandborn, W.J.; Gassull, M.; Schreiber, S.; Jackowski, L.; Butler, T.; Lyne, A.; Stephenson, D.; Palmen, M.; Joseph, R.E. Once-Daily, High-Concentration MMX Mesalamine in Active Ulcerative Colitis. Gastroenterology, 2007, 132, 66-75.
19. Kamm, M.A.; Lichtenstein, G.R.; Sandborn, W.J.; Schreiber, S. Effect of extended MMX Mesalamine therapy for acute, mild-toulcerative colitis. Inflam. Bowel Dis., 2009, 15, 1-8.
20. Kamm, M.A.; Lichtenstein, G.R.; Sandborn, W.J.; Schreiber, S.; Lees, K.; Barrett, K.; Joseph, R. Randomised trial of once-or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut, 2008, 57, 893-902.
21. Lichtenstein, G.R.; Kamm, M.A.; Sandborn, W.J.; Lyne, A.; Joseph, R.E. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. Aliment. Pharmacol. Ther., 2008, 27, 1094-1102.
22. Pastorelli, L.; Saibeni, S.; Spina, L.; Signorelli, C.; Celasco, G.; De Franchis, R. Oral, colonic-release low-molecular-weight heparin: an initial open study of Parnaparin-MMX for the treatment of mildto-moderate left-sided ulcerative colitis. Aliment. Pharmacol. Ther., 2008, 28, 581-588.
23. Brunner, M.; Ziegler, S.; Di Stefano, A.F.D.; Dehghanyar, P.; Kletter, K.; Tschurlovits, M.; Villa, R.; Bozzella, R.; Celasco, G.; Moro, L.; Rusca, A.; Dudczak, R.; Müller, M. Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation. Br. J. Clin. Pharmacol., 2005, 61, 31-38.
24. D'Haens, G.; Kovacs, A.; Vergauwe, P.; Lonovics, J.; Bouhnik, J.; Weiss, W.; Brunner, H.; Lavergne-Slove, A.; Di Stefano, A.; Marteau, P. Budesonide MMX is efficient and safe in patients with active left-sided ulcerative colitis. J. Crohn. Colitis, 2007, 1, Abs, P043.
25. Kedia, P.; Cohen, R.D. Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis. Ther. Clin. Risk Manag., 2007, 3, 919-927.
26. Shale, M.J.; Riley, S.A. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther., 2003, 18, 191-198.
27. http://www.clinicaltrial.gov/ct2/show/NCT00679432?term= Ulcerative+colitis&rank=6.
28. Shen, J.; Ran, Z.H.; Tong, J.L.; Xiao, S.D. Metaanalysis: The utility and safety of heparin in the treatment of active ulcerative colitis. Aliment. Pharmacol. Ther., 2007, 26, 653-663.
29. Pellequer, Y.; Meissner, Y.; Ubrich, N.; Lamprecht, A. Epithelial heparin delivery via microspheres mitigates experimental colitis in mice. J. Pharmacol. Exp. Ther., 2007, 321, 726-733.
30. Celasco, G.; Moro, L.; Bozzella, R.; Mangano, K.; Quattrocchi, C.; Aiello, C.; Donia, M.; Fagone, P.; Di Marco, R. Efficacy of intracolonic administration of low-molecular-weight heparin CB01-05, compared to other low-molecular-weight heparins and unfractionated heparin, in experimentally induced colitis in rat. Digest. Dis. Sci., 2008, 53, 3170-3175.